Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342131 | 0.85 | P2RX7 (0.37) | L3MBTL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL3344860 | 0.82 | LCK (0.51) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30462870 | 0.82 | LCK (0.51) | MAPTKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3347697 | 0.81 | SCN9A (0.35) | MAPTKDM4EALDH1A1LMNATSHR | |
| SCHEMBL3342251 | 0.79 | TSHR (0.33) | MAPTKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL3341052 | 0.78 | MEN1 (0.44) | POLBKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL3347499 | 0.78 | PKM (0.44) | MAPTALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL3341076 | 0.77 | L3MBTL1 (0.48) | L3MBTL1POLBRECQLMAPTKDM4E | |
| SCHEMBL20456341 | 0.77 | KDM4E (0.43) | RECQLMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL7265682 | 0.75 | GAA (0.50) | ALDH1A1LMNASMN1; SMN2RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2393781-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | L3MBTL1 4395/4885POLB 4130/4885RECQL 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.